Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;7(Suppl 8):S367.
doi: 10.21037/atm.2019.08.118.

BRAF mutant metastatic colorectal cancers: new arrows in our quiver

Chiara Cremolini  1   2 , Roberto Moretto  1   2 , Gemma Zucchelli  1   2 , Alfredo Falcone  1   2
Affiliations
Editorial

BRAF mutant metastatic colorectal cancers: new arrows in our quiver

Chiara Cremolini et al. Ann Transl Med. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: C Cremolini reported receiving personal fees from F. Hoffman-La Roche, Bayer, Sirtex, and Amgen. A Falcone reported receiving grants and personal fees from F. Hoffman-La Roche, Amgen, and Merck Serono as well as personal fees from Celgene, Bayer, and Sanofi Aventis. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014;20:5322-30. 10.1158/1078-0432.CCR-14-0332 - DOI - PMC - PubMed
    1. Safaee Ardekani G, Jafarnejad SM, Tan L, et al. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PloS One 2012;7:e47054. 10.1371/journal.pone.0047054 - DOI - PMC - PubMed
    1. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-75. 10.1016/S1470-2045(14)70330-4 - DOI - PubMed
    1. Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014;32:2240-7. 10.1200/JCO.2013.53.2473 - DOI - PubMed
    1. Morris V, Overman MJ, Jiang ZQ, et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 2014;13:164-71. 10.1016/j.clcc.2014.06.001 - DOI - PMC - PubMed